无机碘口服在Graves病中的研究进展

王心盼; 赵成程; 李璐阳; 郑旭琴

doi:10.16766/j.cnki.issn.1674-4152.002781

无机碘口服在Graves病中的研究进展

doi: 10.16766/j.cnki.issn.1674-4152.002781

南京医科大学第一附属医院内分泌科，江苏南京 210029

基金项目:

江苏省研究生科研与实践创新计划项目 SJCX22_0681

江苏省研究生科研与实践创新计划项目 SJCX20_0494

详细信息

通讯作者:
郑旭琴，E-mail：zhengxuqin@njmu.edu.cn

中图分类号: R581.3
计量
- 文章访问数: 253
- HTML全文浏览量: 84
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-10
- 网络出版日期: 2023-02-07

Research progress of oral inorganic iodine for Graves' disease

Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

摘要

摘要: 碘是人体内重要微量元素之一，是甲状腺激素合成的基本原料。口服的无机碘分为膳食碘和治疗碘，与甲状腺免疫和代谢密切相关。Graves病(Graves ' disease，GD)又称弥漫性毒性甲状腺肿，表现为甲状腺功能亢进及高碘代谢状态，临床上常建议Graves病患者限碘甚至忌碘饮食。最新的研究进展显示膳食碘对于抗甲状腺药物治疗的干扰性可能被高估，放射性碘治疗之前严格限制无机碘、择期手术之前强制使用无机碘都不是必需的。此外，无机碘可以作为Graves病的治疗药物，在具有轻型甲亢、低甲状腺自身抗体浓度、较小的甲状腺体积、高碘饮食等特点的患者中探索性应用无机碘显示出不错的成效。当传统的抗甲状腺药物出现副作用而患者仍倾向保守治疗时，无机碘或许能作为替代选择。无机碘因低致畸性、低血液毒性和低骨髓毒性，可以在特殊人群如妊娠期、哺乳期和肿瘤放化疗期的患者中发挥独特作用。本文对膳食碘和治疗碘的研究进程、生物学功能、适用人群及特定情形下的应用进行汇总，旨在为Graves病的诊治提供参考，丰富Graves病患者的诊疗策略以及进一步提高Graves病患者的生存质量。
- 无机碘 /
- Graves病 /
- 饮食 /
- 治疗 /
- 特殊人群
Abstract: Iodine is one of the important trace elements in the human body and the basic raw material for thyroid hormone synthesis. Oral inorganic iodine is divided into dietary and therapeutic iodine and is closely related to thyroid immunity and metabolism. Graves' disease (GD), also known as diffuse toxic goitre, is characterised by hyperthyroidism and high iodine metabolism. Clinically, we often advise patients with GD to limit or avoid iodine diet. The latest research progress shows that the interference of dietary iodine in antithyroid drug therapy may be overestimated, and strict restriction of inorganic iodine before radioactive iodine therapy and the use of inorganic iodine compulsorily before elective surgery are unnecessary. In addition, inorganic iodine can be used as a therapeutic drug for GD, and its exploratory application in patients with mild hyperthyroidism, low thyroid autoantibody concentration, small thyroid volume and high iodine diet has shown good results. When traditional antithyroid drugs have side effects, and patients still prefer conservative treatment, inorganic iodine may be an alternative. Given its low teratogenicity, blood toxicity and bone marrow toxicity, inorganic iodine can play a unique role in special groups, such as patients in pregnancy, lactation and tumour radiotherapy and chemotherapy. This paper summarises the research progress, biological function, applicable population and application under specific circumstances of dietary and therapeutic iodine to provide reference for the diagnosis and treatment of GD, enrich the diagnosis and treatment strategies of GD patients and further improve the quality of life of GD patients.
- Inorganic iodine /
- Graves' disease /
- Diet /
- Treatment /
- Special groups of people

HTML全文

参考文献(36)

[1]	RUMP A, EDER S, HERMANN C, et al. Modeling principles of protective thyroid blocking[J]. Int J Radiat Biol, 2022, 98(5): 831-842. doi: 10.1080/09553002.2021.1987570
[2]	LLORENTE-ESTEBAN A, MANVILLE R W, REYNA-NEYRA A, et al. Allosteric regulation of mammalian Na⁺/I^- symporter activity by perchlorate[J]. Nat Struct Mol Biol, 2020, 27(6): 533-539. doi: 10.1038/s41594-020-0417-5
[3]	VAN GEEST F S, GUNHANLAR N, GROENEWEG S, et al. Monocarboxylate transporter 8 deficiency: From pathophysiological understanding to therapy development[J]. Front Endocrinol(Lausanne), 2021, 12: 723750. DOI: 10.3389/fendo.2021.723750.
[4]	ELEFTHERIADOU A M, MEHL S, RENKO K, et al. Re-visiting autoimmunity to sodium-iodide symporter and pendrin in thyroid disease[J]. Eur J Endocrinol, 2020, 183(6): 571-580. doi: 10.1530/EJE-20-0566
[5]	CHARTOUMPEKIS D V, ZIROS P G, GEORGAKOPOULOS-SOARES I, et al. The transcriptomic response of the murine thyroid gland to iodide overload and the role of the Nrf2 antioxidant system[J]. Antioxidants (Basel), 2020, 9(9): 884. doi: 10.3390/antiox9090884
[6]	ZIMMERMANN M B, ANDERSSON M. GLOBAL ENDOCRINOLOGY: Global perspectives in endocrinology: Coverage of iodized salt programs and iodine status in 2020[J]. Eur J Endocrinol, 2021, 185(1): R13-R21. doi: 10.1530/EJE-21-0171
[7]	ZIMMERMANN M B. Salt iodization halves risk of thyrotoxicosis in Denmark[J]. Nat Rev Endocrinol, 2019, 15(11): 632-633. doi: 10.1038/s41574-019-0261-z
[8]	LI Y Z, TENG D, BA J M, et al. Efficacy and safety of long-term universal salt iodization on thyroid disorders: Epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020, 30(4): 568-579. doi: 10.1089/thy.2019.0067
[9]	WANG C, LI Y, TENG D, et al. Hyperthyroidism prevalence in China after universal salt iodization[J]. Front Endocrinol(Lausanne), 2021, 12: 651534. DOI: 10.3389/fendo.2021.651534.
[10]	LI Y Z, SHAN Z Y, TENG W P. Effect of the transition from more than adequate iodine to adequate iodine on national changes in the prevalence of thyroid disorders: Repeat national cross-sectional surveys in China[J]. Eur J Endocrinol, 2021, 186(1): 115-122.
[11]	WANG H R, JIANG Y S, SONG J Y, et al. The risk of perchlorate and iodine on the incidence of thyroid tumors and nodular goiter: A case-control study in southeastern china[J]. Environ Health, 2022, 21(1): 4. doi: 10.1186/s12940-021-00818-8
[12]	CHUNG J H. Antithyroid drug treatment in Graves' disease[J]. Endocrinol Metab (Seoul), 2021, 36(3): 491-499. doi: 10.3803/EnM.2021.1070
[13]	SORRENTI S, BALDINI E, PIRONI D, et al. Iodine: Its role in thyroid hormone biosynthesis and beyond[J]. Nutrients, 2021, 13(12): 4469. doi: 10.3390/nu13124469
[14]	HUANG H B, SHI Y X, LIANG B, et al. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction[J]. Clin Endocrinol (Oxf), 2018, 88(3): 473-478. doi: 10.1111/cen.13543
[15]	SUZUKI N, YOSHIMURA NOH J, SUGISAWA C, et al. Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease[J]. Endocr J, 2020, 67(6): 631-638. doi: 10.1507/endocrj.EJ19-0379
[16]	YOSHIHARA A, NOH J Y, WATANABE N, et al. Characteristics of patients with Graves' disease whose thyroid hormone levels increase after substituting potassium iodide for methimazole in the first trimester of pregnancy[J]. Thyroid, 2020, 30(3): 451-456. doi: 10.1089/thy.2019.0392
[17]	KAMIJO K. Clinical studies on potassium iodide-induced painless thyroiditis in 11 Graves' disease patients[J]. Intern Med, 2021, 60(11): 1675-1680. doi: 10.2169/internalmedicine.6411-20
[18]	YOSHIHARA A, NOH J Y, WATANABE N, et al. Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: A retrospective study at a single medical institution in Japan[J]. Thyroid, 2015, 25(10): 1155-1161. doi: 10.1089/thy.2014.0581
[19]	RAMHØJ L, SVINGEN T, FRÄDRICH C, et al. Perinatal exposure to the thyroperoxidase inhibitors methimazole and amitrole perturbs thyroid hormone system signaling and alters motor activity in rat offspring[J]. Toxicol Lett, 2022, 354: 44-55. doi: 10.1016/j.toxlet.2021.10.010
[20]	KARAOGLAN M, IꞩBILEN E. The role of placental iodine storage in the neonatal thyroid stimulating hormone surge: Iodine as a driving force to adapt the terrestrial life[J]. J Endocrinol Invest, 2021, 44(5): 1041-1052. doi: 10.1007/s40618-020-01399-y
[21]	ŽABKOVÁ K, KRÁTKỲ J, JISKRA J, et al. The importance of iodine nutrition during pregnancy-clinical aspect[J]. Cas Lek Cesk, 2021, 160(6): 224-228.
[22]	ZHANG L, FAN L J, LI F, et al. Study on the effect of different iodine intake on hippocampal metabolism in offspring rats[J]. Biol Trace Elem Res, 2022, 200(10): 4385-4394. doi: 10.1007/s12011-021-03032-2
[23]	DU Y, LIU P, MENG F G, et al. What iodine intervention measures should be taken in different water iodine areas? Evidence from a cross-sectional chinese survey[J]. Biol Trace Elem Res, 2022, 200(11): 4654-4663. doi: 10.1007/s12011-021-03050-0
[24]	HAMADA K, MIZOKAMI T, MARUTA T, et al. Thyroid function of infants breastfed by mothers with Graves disease treated with inorganic iodine: A study of 100 cases[J]. J Endocr Soc, 2021, 5(2): bvaa187. DOI: 10.1210/jendso/bvaa187.
[25]	ANDERSSON M, BRAEGGER C P. The role of iodine for thyroid function in lactating women and infants[J]. Endocr Rev, 2022, 43(3): 469-506. doi: 10.1210/endrev/bnab029
[26]	BENLARBI H, SIMON D, ROSENBLATT J, et al. Prevalence and course of thyroid dysfunction in neonates at high risk of Graves' disease or with non-autoimmune hyperthyroidism[J]. Eur J Endocrinol, 2021, 184(3): 427-436. doi: 10.1530/EJE-20-1320
[27]	MAXIMIANO C, SILVA M R, CARVALHO F, et al. Follow-up of infants born to mothers with Graves' disease[J]. Endocrinol Diabetes Nutr (Engl Ed), 2021, 68(7): 472-480.
[28]	王越, 陈信. 30例低三碘甲状腺原氨酸综合征临床观察[J]. 中华全科医学, 2021, 19(4): 596-598. doi: 10.16766/j.cnki.issn.1674-4152.001870 WANG Y, CHEN X. Clinical research of 30 premature infants with lowhypotriiodothyronine syndrome[J]. Chinese Journal of General Practice, 2021, 19(4): 596-598. doi: 10.16766/j.cnki.issn.1674-4152.001870
[29]	OKAMURA K, BANDAI S, FUJIKAWA M, et al. Clinical experience of treating Graves' hyperthyroidism complicated with malignancy-the possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia[J]. Endocr J, 2020, 67(7): 751-758. doi: 10.1507/endocrj.EJ20-0016
[30]	BARRANQUERO A G, MUÑOZ DE NOVA J L, GÓMEZ-RAMÍREZ J, et al. Effect of preoperative potassium iodide administration on Graves' disease surgery: A propensity score analysis[J]. Am J Surg, 2021, 222(5): 959-963. doi: 10.1016/j.amjsurg.2021.04.023
[31]	ALI A, DEBONO M, BALASUBRAMANIAN S P. Outcomes after urgent thyroidectomy following rapid control of thyrotoxicosis in Graves' disease are similar to those after elective surgery in well-controlled disease[J]. World J Surg, 2019, 43(12): 3051-3058. doi: 10.1007/s00268-019-05125-5
[32]	CHIAPPONI C, SCHMIDT M, FAUST M. Potassium iodide tablets instead of a saturated solution preoperatively for reaching euthyroidism quickly in refractory Graves' disease[J]. Cureus, 2021, 13(6): e15854. DOI: 10.7759/cureus.15854.
[33]	NISHIO R, UCHIDA T, SUZUKI L, et al. Influence of short-term dietary and therapeutic iodine restriction on the therapeutic effects of radioactive iodine therapy in patients with Graves' disease[J]. Thyroid, 2021, 31(3): 439-445. doi: 10.1089/thy.2020.0126
[34]	LEE H, PAENG J C, CHOI H, et al. Effect of tsh stimulation protocols on adequacy of low-iodine diet for radioiodine administration[J]. PLoS One, 2021, 16(9): e0256727. DOI: 10.1371/journal.pone.0256727.
[35]	DAFFINI L, PIROLA I, SACCÀ G, et al. Graves' disease treated by complementary medicine leading to thyroid storm: A case report[J]. Caspian J Intern Med, 2021, 12(Suppl 2): S371-S375.
[36]	DHAMI A, IQBAL A, NOVODVORSKY P, et al. Coronary artery spasm-induced cardiac arrest precipitated by iodine contrast load in unknown pre-existing Graves' disease[J]. JACC Cardiovasc Interv, 2020, 13(16): e147-e149. doi: 10.1016/j.jcin.2020.05.029